PE20060434A1 - Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph - Google Patents

Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph

Info

Publication number
PE20060434A1
PE20060434A1 PE2005000677A PE2005000677A PE20060434A1 PE 20060434 A1 PE20060434 A1 PE 20060434A1 PE 2005000677 A PE2005000677 A PE 2005000677A PE 2005000677 A PE2005000677 A PE 2005000677A PE 20060434 A1 PE20060434 A1 PE 20060434A1
Authority
PE
Peru
Prior art keywords
hpv
cancer
plv
capsomers
another type
Prior art date
Application number
PE2005000677A
Other languages
English (en)
Spanish (es)
Inventor
Serge Debrus
Marie-Therese Martin
Martine Anne Cecile Wettendorff
Robert John Stephen
Jean Stephenne
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0413510.9A external-priority patent/GB0413510D0/en
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20060434A1 publication Critical patent/PE20060434A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2005000677A 2004-06-16 2005-06-14 Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph PE20060434A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine

Publications (1)

Publication Number Publication Date
PE20060434A1 true PE20060434A1 (es) 2006-06-08

Family

ID=35160037

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000677A PE20060434A1 (es) 2004-06-16 2005-06-14 Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph

Country Status (18)

Country Link
EP (1) EP1758609B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2008502633A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20070029254A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR049354A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2005253723B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0512042B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2566620C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (2) FR15C0084I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL179138A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (3) LU92899I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA28692B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA06014515A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20070195L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20060434A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL1758609T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2420313C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG153837A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2005123125A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG159529A1 (en) * 2005-04-26 2010-03-30 Glaxosmithkline Biolog Sa Vaccine
WO2010012780A1 (en) * 2008-07-31 2010-02-04 Glaxosmithkline Biologicals S.A. Vaccine against hpv
PL2444103T3 (pl) * 2009-06-19 2018-05-30 Eyegene Inc. Szczepionka przeciwko rakowi szyjki macicy
KR20130142104A (ko) * 2010-07-15 2013-12-27 브리티쉬 콜롬비아 캔써 에이전시 브랜치 인간 파필로마바이러스 e7 항원 조성물 및 이의 용도
KR20150076244A (ko) 2012-10-30 2015-07-06 레드박스 게엠베하 인간 시토메갈로바이러스 감염에 대한 재조합 입자 기재 백신
MY195018A (en) * 2014-10-24 2023-01-03 Hpvvax Llc Cancer and skin lesion treatment
CN107188966B (zh) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CA2510457C (en) * 2002-12-20 2011-12-06 Glaxosmithkline Biologicals S.A. Hpv-16 and -18 l1 vlp vaccine

Also Published As

Publication number Publication date
FR15C0082I2 (fr) 2016-10-28
EP1758609B1 (en) 2012-10-03
FR15C0084I2 (fr) 2016-10-28
RU2420313C2 (ru) 2011-06-10
BRPI0512042A (pt) 2008-02-06
BRPI0512042B8 (pt) 2021-05-25
EP1758609A1 (en) 2007-03-07
RU2006143804A (ru) 2008-08-20
PL1758609T3 (pl) 2013-02-28
FR15C0082I1 (fr) 2016-01-08
FR15C0084I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-01-08
MXPA06014515A (es) 2007-03-23
LU92899I2 (fr) 2016-03-08
CA2566620A1 (en) 2005-12-29
IL179138A0 (en) 2007-03-08
LU92900I2 (fr) 2016-03-08
SG153837A1 (en) 2009-07-29
AU2005253723B2 (en) 2011-01-20
WO2005123125A1 (en) 2005-12-29
LU92898I2 (fr) 2016-03-08
NO20070195L (no) 2007-01-15
AU2005253723A1 (en) 2005-12-29
BRPI0512042B1 (pt) 2019-01-22
MA28692B1 (fr) 2007-06-01
JP2008502633A (ja) 2008-01-31
CA2566620C (en) 2014-03-11
AR049354A1 (es) 2006-07-19
KR20070029254A (ko) 2007-03-13

Similar Documents

Publication Publication Date Title
PE20120476A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
AR083679A1 (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos
PA8554501A1 (es) Composicion fungicida basada en derivados de arilamidina y compuestos fungicos conocidos
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
AR061887A1 (es) Una composicion de vacuna contra el dengue
ECSP066959A (es) Compuestos macrociclicos como inhibidores de la replicación viral
ECSP077412A (es) Derivados de indol tetracíclicos como agentes antivíricos
CL2011002286A1 (es) Uso de compuestos derivados de nucleosidos para tratar una enfermedad viral; compuestos derivados de nucleosidos; y composicion farmaceutica que comprende los compuestos.
AR040204A1 (es) Composicion de vacuna meningococica multivalente
AR076040A1 (es) Composicion que comprende al menos un compuesto flavonoide, con la condicion de que el compuesto flavonoide no sea hesperetina, y hesperetina
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
CL2008002228A1 (es) Compuestos derivados de imidazopiridinonas, agonista de tlr7; procedimiento de preparacion; compuestos intermediarios; composiicon farmaceutica que los comprende; y uso en infecciones virales, bacterianas y fungicas.
EA200701632A1 (ru) Вакцина против вируса ветряной оспы
CL2008003762A1 (es) Composicion concentrada en suspension acuosa para proteccion de cultivos, que comprende un compuesto activo y como agentes estabilizadores, un disperzante no ionico y un dsipersante anionico y agua; metodos para preparacion de dicha composicion y usos de la misma, para el cuidado de cultivos de interes.
MX2021000376A (es) Composiciones tópicas para el alivio del dolor.
AR079706A1 (es) Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso
CO5611105A2 (es) Material micronizado cristalino de bromuro de tiotropio
CU20090112A6 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
PE20060434A1 (es) Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph
PE20060002A1 (es) Combinaciones antineoplasicas de cci-779 y rituximab
CR9425A (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
AR044123A1 (es) Composicion de acido rosmarinico
MX2013000242A (es) Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.
AR090999A1 (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos
AR121292A1 (es) Vacuna contra hpv

Legal Events

Date Code Title Description
FC Refusal